China And US Added to Amneal-Iconovo Symbicort Alliance
Expands Agreement Disclosed In May Last Year
Swedish player Iconovo is in line for larger future royalties through its partnership with Amneal covering a generic version of AstraZeneca’s Symbicort, after the two firms signed a new, expanded agreement.
You may also be interested in...
Viatris may be able to move earlier than anticipated with its Breyna proposed generic version of Symbicort, after the US Court of Appeals for the Federal Circuit found that a lower court had misinterpreted claims of Symbicort patents for which Viatris has stipulated to infringement.
Viatris and partner Kindeva Drug Delivery are celebrating a first tentative nod for a generic to one of the most significant respiratory opportunities in the US, but cannot launch at present with the firms having failed to navigate key pieces of intellectual property.
In a much watched and controversial case that may have significant ramifications on the “chilling effects” of generics manufacturers in Israel being deterred from chasing after approvals in which an originator has deceitfully sought to ‘evergreen’ its branded intellectual property, the Israeli Supreme Court has once again come down on the side of the generics industry.